Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells

British Journal of Pharmacology

Volumn 153, Issue 5, 2008, Pages 1003-1010

  Malfitano, A M ^a   Laezza, C ^b   Pisanti, S ^a   Gazzerro, P ^a   Bifulco, M ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

Antiproliferative response; Immunomodulation; Inflammation; Rimonabant

Indexed keywords

2 METHYLARACHIDONYL 2' FLUORO ETHYLAMIDE; CANNABINOID RECEPTOR AGONIST; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; RIMONABANT; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 40149102381     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707651     Document Type: Article

References (38)

1. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V (2004). A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606–1608.
2. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi‐Carmona M, Portier M et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen‐activated protein kinase activation stimulated by insulin or insulin‐like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272: 22330–22339.
3. Bouaboula M, Rinaldi M, Carayon O, Delpech B, Shire D, Le Fur G et al. (1993). Cannabinoid‐receptor expression in human leukocytes. Eur J Biochem 214: 173–180.
4. Carai MA, Colombo G, Gessa GL (2005). Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77: 2339–2350.
5. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517–1524.
6. Chou TC, Talalay P (1984). Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.
7. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: PL113–PL117.
8. Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T (2005). Effect of the cannabinoid CB 1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116: 52–61.
9. Croci T, Landi M, Galzin AM, Marini P (2003). Role of cannabinoid CB 1 receptors and tumor necrosis factor‐alpha in the gut and systemic anti‐inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115–122.
10. Croci T, Zarini E (2007). Effect of the cannabinoid CB 1 receptor antagonist rimonabant on nociceptive responses and adjuvant‐induced arthritis in obese and lean rats. Br J Pharmacol 150: 559–566.
11. Di Marzo V, Matias I (2005). Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585–589.
12. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838–2843.
13. Gary‐Bobo M, Elachouri G, Scatton B, Le Fur G, Oury‐Donat F, Bensaid M (2006). The cannabinoid CB 1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69: 471–478.
14. Ghosh S, May MJ, Kopp EB (1998). NF‐kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225–260.
15. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M et al. (2006). Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312: 363–373.
16. Hurst DP, Lynch DL, Barnett‐Norris J, Hyatt SM, Seltzman HH, Zhong M et al. (2002). N ‐(piperidin‐1‐yl)‐5‐(4‐chlorophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1 H ‐pyrazole‐3‐carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB 1 receptor. Mol Pharmacol 62: 1274–1287.
17. Jbilo O, Ravinet‐Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. (2005). The CB 1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19: 1567–1569.
18. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992). Identification of a functional relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid‐mediated immune modulation. Mol Pharmacol 42: 736–742.
19. Kane LP, Lin J, Weiss A (2000). Signal transduction by the TCR for antigen. Curr Opin Immunol 12: 242–249.
20. Karin M, Ben‐Neriah Y (2000). Phosphorylation meets ubiquitination: the control of NF‐[kappa]B activity. Annu Rev Immunol 18: 621–663.
21. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L et al. (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74: 486–496.
22. Lawlor MA, Rotwein P (2000). Insulin‐like growth factor‐mediated muscle cell survival: central roles for Akt and cyclin‐dependent kinase inhibitor p21. Mol Cell Biol 20: 8983–8995.
23. Malfitano AM, Matarese G, Pisanti S, Grimaldi C, Laezza C, Bisogno T et al. (2006). Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 171: 110–119.
24. Malfitano AM, Toruner GA, Gazzerro P, Laezza C, Husain S, Eletto D et al. (2007). Arvanil and anandamide up‐regulate CD36 expression in human peripheral blood mononuclear cells. Immunol Lett 109: 145–154.
25. Márquez N, De Petrocellis L, Caballero FJ, Macho A, Schiano‐Moriello A, Minassi A et al. (2006). Iodinated N ‐acylvanillamines: potential ‘multiple‐target’ anti‐inflammatory agents acting via the inhibition of T‐cell activation and antagonism at vanilloid TRPV1 channels. Mol Pharmacol 69: 1373–1382.
26. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. (2006). Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta‐pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171–3180.
27. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M et al. (1999). Unsaturated long‐chain N ‐acyl‐vanillyl‐amides (N ‐AVAMs): vanilloid receptor ligands that inhibit anandamide‐facilitated transport and bind to CB 1 cannabinoid receptor. Biochem Biophys Res Commun 262: 275–284.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271–279.
29. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. (2003). Anti‐obesity effect of SR 141716, a CB 1 receptor antagonist, in diet‐induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345–R353.
30. Rinaldi‐Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C et al. (1995). Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941–1947.
31. Rinaldi‐Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240–244.
32. Sancho R, Calzado MA, Di Marzo V, Appendino G, Munoz E (2003). Anandamide inhibits nuclear factor‐kappaB activation through a cannabinoid receptor‐independent pathway. Mol Pharmacol 63: 429–438.
33. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C et al. (2006). The cannabinoid CB 1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft‐mediated mechanism. Mol Pharmacol 70: 1298–1306.
34. Schatz AR, Lee M, Condie R, Pulaski J, Kaminski NE (1997). Cannabinoid receptors CB 1 and CB 2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142: 278–287.
35. Simiand J, Keane M, Keane PE, Soubrié P (1998). SR 141716, a CB 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9: 179–181.
36. Smith SR, Terminelli C, Denhardt G (2000). Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti‐inflammatory interleukin‐10 in endotoxemic mice. J Pharmacol Exp Ther 293: 136–150.
37. Tak PP, Firestein GS (2001). NF‐kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7–11.
38. Whitehurst CE, Boulton TG, Cobb MH, Geppert TD (1992). Extracellular signal‐regulated kinases in T cells: anti‐CD3 and 4 β‐phorbol 12‐myristate 13‐acetate‐induced phosphorylation and activation. J Immunol 148: 3230–3237.